Intratumoral heterogeneity of HER2 gene amplification in breast cancer: Its clinicopathological significance

Modern Pathology

Volumn 25, Issue 7, 2012, Pages 938-948

  Seol, Hyesil ^a   Lee, Hyun Ju ^a   Choi, Yoomi ^b   Lee, Hee Eun ^b   Kim, Yu Jung ^a   Kim, Jee Hyun ^a,c   Kang, Eunyoung ^a   Kim, Sung Won ^a,c   Park, So Yeon ^a,c  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

breast carcinoma; fluorescence in situ hybridization; gene amplification; HER2; intratumoral heterogeneity

Indexed keywords

ANTHRACYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INVASION; CANCER PROGNOSIS; CLINICAL EVALUATION; CLINICAL EXAMINATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; GENE AMPLIFICATION; GENETIC HETEROGENEITY; GENETIC STABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY;

EID: 84863470138     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.36     Document Type: Article

References (38)

1. Press MF, Pike MC, Chazin VR, et al. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993;53:4960-4970. (Pubitemid 23326194)
2. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235: 177-182. (Pubitemid 17231334)
3. Tandon AK, Clark GM, Chamness GC, et al. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989;7:1120-1128. (Pubitemid 19196537)
4. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684. (Pubitemid 41464706)
5. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-726. (Pubitemid 34111379)
6. Madarnas Y, Trudeau M, Franek JA, et al. Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review. Cancer Treat Rev 2008;34:539-557.
7. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145. (Pubitemid 350003059)
8. Gong Y, Booser DJ, Sneige N. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 2005;103:1763-1769. (Pubitemid 40563246)
9. Tanner M, Jarvinen P, Isola J. Amplification of HER-2/neu and topoisomerase II alpha in primary and metastatic breast cancer. Cancer Res 2001;61: 5345-5348. (Pubitemid 32694907)
10. Gancberg D, Di Leo A, Cardoso F, et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002;13:1036-1043.
11. Fabi A, Di Benedetto A, Metro G, et al. HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care. Clin Cancer Res 2011;17:2055-2064.
12. Meng S, Tripathy D, Shete S, et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 2004;101:9393-9398. (Pubitemid 38812885)
13. Regitnig P, Schippinger W, Lindbauer M, et al. Change of HER-2/neu status in a subset of distant metastases from breast carcinomas. J Pathol 2004;203:918-926. (Pubitemid 39089280)
14. Lower EE, Glass E, Blau R, et al. HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 2009;113:301-306.
15. Andersson J, Linderholm B, Bergh J, et al. HER-2/neu (c-erbB-2) evaluation in primary breast carcinoma by fluorescent in situ hybridization and immunohistochemistry with special focus on intratumor heterogeneity and comparison of invasive and in situ components. Appl Immunohistochem Mol Morphol 2004;12:14-20. (Pubitemid 38332313)
16. Brunelli M, Manfrin E, Martignoni G, et al. Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria. Am J Clin Pathol 2009;131: 678-682.
17. Glockner S, Buurman H, Kleeberger W, et al. Marked intratumoral heterogeneity of c-myc and cyclin D1 but not of c-erbB2 amplification in breast cancer. Lab Invest 2002;82:1419-1426. (Pubitemid 35191545)
18. Hanna W, Nofech-Mozes S, Kahn HJ. Intratumoral heterogeneity of HER2/neu in breast cancer-a rare event. Breast J 2007;13:122-129. (Pubitemid 46280606)
19. Vance GH, Barry TS, Bloom KJ, et al. Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med 2009; 133:611-612.
20. Cottu PH, Asselah J, Lae M, et al. Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer. Ann Oncol 2008;19:595-597.
21. Lewis JT, Ketterling RP, Halling KC, et al. Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining. Am J Clin Pathol 2005;124:273-281. (Pubitemid 41060140)
22. Striebel JM, Bhargava R, Horbinski C, et al. The equivocally amplified HER2 FISH result on breast core biopsy: indications for further sampling do affect patient management. Am J Clin Pathol 2008;129:383-390. (Pubitemid 352029290)
23. Shin SJ, Hyjek E, Early E, et al. Intratumoral heterogeneity of her-2/neu in invasive mammary carcinomas using fluorescence in-situ hybridization and tissue microarray. Int J Surg Pathol 2006;14:279-284. (Pubitemid 44545764)
24. Moeder CB, Giltnane JM, Harigopal M, et al. Quantitative justification of the change from 10 to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome. J Clin Oncol 2007;25:5418-5425. (Pubitemid 350232218)
25. Bartlett AI, Starcyznski J, Robson T, et al. Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition. Am J Clin Pathol 2011;136:266-274.
26. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28: 2784-2795.
27. Hyun CL, Lee HE, Kim KS, et al. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer. J Clin Pathol 2008;61:317-321. (Pubitemid 351354237)
28. Ma Y, Lespagnard L, Durbecq V, et al. Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice. Clin Cancer Res 2005;11:4393-4399. (Pubitemid 40825629)
29. Jackson AL, Loeb LA. The mutation rate and cancer. Genetics 1998;148:1483-1490. (Pubitemid 28180678)
30. Park SY, Gonen M, Kim HJ, et al. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest 2010;120:636-644.
31. Szollosi J, Balazs M, Feuerstein BG, et al. ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer. Cancer Res 1995;55:5400-5407.
32. Carter SL, Eklund AC, Kohane IS, et al. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 2006;38:1043-1048. (Pubitemid 44325930)
33. Burrell RA, Juul N, Johnston SR, et al. Targeting chromosomal instability and tumour heterogeneity in HER2-positive breast cancer. J Cell Biochem 2010; 111:782-790.
34. Heppner GH, Miller BE. Tumor heterogeneity: biological implications and therapeutic consequences. Cancer Metastasis Rev 1983;2:5-23.
35. Merlo LM, Pepper JW, Reid BJ, et al. Cancer as an evolutionary and ecological process. Nat Rev Cancer 2006;6:924-935. (Pubitemid 44862677)
36. Arnould L, Arveux P, Couturier J, et al. Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification. Clin Cancer Res 2007;13:6404-6409. (Pubitemid 350075030)
37. D'Alfonso T, Liu YF, Monni S, et al. Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed. Am J Surg Pathol 2010;34:575-581.
38. Wu JM, Halushka MK, Argani P. Intratumoral heterogeneity of HER-2 gene amplification and protein overexpression in breast cancer. Hum Pathol 2010;41: 914-917.